Where there is a call for innovation and flexibility to respond to specific needs, as in the
development of new drugs and equipment, markets are better. But direct market interactions between patients and providers in the health sector have the major disadvantage of exposing individuals to the financial risks of illness unless the financial resources are adequately pooled. And it is difficult or impossible to assure that such transactions respect any priorities among interventions and patients that the health system is trying to implement.